ANVISA approved BridgeBio’s acoramidis on May 6 for ATTR-CM in an all-comers indication, citing ATTRibute-CM data showing 42% reduction in all-cause mortality and cardiovascular hospitalizations at 30 months.
ANVISA approved BridgeBio’s acoramidis on May 6 for ATTR-CM in an all-comers indication, citing ATTRibute-CM data showing 42% reduction in all-cause mortality and cardiovascular hospitalizations at 30 months.
You must be logged in to post a comment.